Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP1011T in advanced solid tumors: Phase I/II dose-escalation and expansion study
ChiCTR2400088650Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ABP1011T in Non-hematologic malignancy, colorectal cancer (CRC), bladder cancer and 4 more (12 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose-limiting toxicity (DLT), Maximum tolerated dose (MTD) and 2 more. Started Aug 2024; status: recruiting.
02
Drugs
ABP1011T
03
Conditions
Non-hematologic malignancycolorectal cancer (CRC)bladder cancergastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2400088650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088650.